APA (7th ed.) Citation

Xu, Y., Gao, X., Chen, M., Liu, X., Zhao, J., Zhong, W., & Wang, M. A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (Anti-PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy. Elsevier.

Chicago Style (17th ed.) Citation

Xu, Yan, Xiaoxing Gao, Minjiang Chen, Xiaoyan Liu, Jing Zhao, Wei Zhong, and Mengzhao Wang. A Phase 2 Study of Pembrolizumab in Combination with Plinabulin and Docetaxel in Previously Treated Patients with Metastatic Non-small Cell Lung Cancer and Progressive Disease (PD) After Immunotherapy (Anti-PD-1/PD-L1 Inhibitor) Alone or in Combination with Platinum-doublet Chemotherapy. Elsevier.

MLA (9th ed.) Citation

Xu, Yan, et al. A Phase 2 Study of Pembrolizumab in Combination with Plinabulin and Docetaxel in Previously Treated Patients with Metastatic Non-small Cell Lung Cancer and Progressive Disease (PD) After Immunotherapy (Anti-PD-1/PD-L1 Inhibitor) Alone or in Combination with Platinum-doublet Chemotherapy. Elsevier.